 BeyondSpring Inc NASDAQ: BYSI is trading significantly lower Wednesday after the company announced it received a Complete Response Letter CRL from the U.S. Food and Drug Administration FDA for the plinabulin NDA for prevention of chemotherapy-induced neutropenia. The FDA issued the CRL to indicate that they have completed their review of the application and have determined that it cannot be approved in its current form. 